Pfizer Inc (PFE) 33.00 $PFE
Is This The Biggest Roadblock to a Pfizer-Allergan Merger?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 7:29AM CST
Pfizer and Allergan are reportedly discussing the possibility of a friendly merger between the two pharma giants that could take place before year's end. This proposed deal has drawn broad interest in the media because of the so-called 'tax...
AGN: 296.40 (-2.31), PFE: 33.00 (-0.16)
Roche's Lung Cancer Diagnostic Test Approved in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:05PM CST
Roche announced that the FDA has approved its diagnostic test, the cobas EGFR Mutation Test v2, for companion diagnostic use.
NVO: 53.87 (+0.61), PFE: 33.00 (-0.16), AZN: 33.34 (+0.56)
The Medicines Co. Up, Angiomax Patent Ruling Overturned
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 3:40PM CST
The Medicines Company's (MDCO) request for rehearing of the appeal has been granted related to its patent infringement lawsuit for Angiomax.
MDCO: 41.16 (-0.35), PFE: 33.00 (-0.16), MYL: 50.64 (+0.64), NVS: 87.47 (+0.42)
Marriott, Not Hyatt Or Chinese Firms, To Buy Starwood
at Investor's Business Daily - Mon Nov 16, 11:18AM CST
Several companies -- including Hyatt (H) and several Chinese bidders -- had been rumored to be in talks to buy Starwood Hotels & Resorts Worldwide (HOT), but Bethesda, Md.-based Marriott International (MAR) will ultimately acquire the hotel chain in...
BUD: 124.72 (+2.33), NSC: 86.88 (-1.42), PFE: 33.00 (-0.16), IILG: 15.40 (-0.04), HAL: 38.18 (-0.31), H: 49.52 (-1.70), MAR: 72.86 (-0.86), AET: 105.34 (+0.33), HOT: 71.79 (-0.48), RAD: 7.76 (+0.02), HUM: 169.08 (+0.04), AGN: 296.40 (-2.31), CI: 133.79 (+0.30), ANTM: 135.70 (+0.64), WBA: 82.68 (+0.84), CP: 139.05 (+1.66), BHI: 49.52 (+0.13)
Next Support Level for Pfizer (PFE) is $32.82
Comtex SmarTrend(R) - Mon Nov 16, 10:18AM CST
Shares of Pfizer (NYSE
FE) opened today below their pivot of $33.36 and have already reached the first level of support at $33.05. Should the shares continue to fall, the support pivots of $32.82 and $32.28 will be of interest.
PFE: 33.00 (-0.16)
3 High-Yield Dividend Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Nov 16, 8:19AM CST
Image by Markgraf-Ave via Pixabay With the S&P 500 once again in negative territory for the year, companies of all sizes have seen their share prices decline. When a stock that pays a strong dividend goes down, it has the happy effect of...
PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), ABBV: 60.22 (+0.21)
Global Anti-Inflammatory Therapeutics Market 2014-2020 by Indication, Drug Class & Geography
PR Newswire Europe - Mon Nov 16, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/8rkdpz/world [http://www.researchandmarkets.com/research/8rkdpz/world]) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" [http://www.researchandmarkets.com/research/8rkdpz/world] report to their offering.
JNJ: 101.31 (+0.09), PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), AZN: 33.33 (+0.55), AMGN: 157.88 (+3.38), ABBV: 60.22 (+0.21), GSK: 40.58 (+0.35), NVS: 87.47 (+0.42)
Nov. 16 Premarket Briefing: Marriott to Buy Starwood
at The Street - Mon Nov 16, 6:00AM CST
U.S. stock futures rise Monday, while European stocks are mixed in choppy trading following the terrorist attacks in Paris on Friday that left at least 129 people dead.
GE: 30.01 (-0.35), CCL: 50.19 (-0.58), A: 38.23 (+0.90), PFE: 33.00 (-0.16), MAR: 72.86 (-0.86), HOT: 71.79 (-0.48), DDS: 73.13 (+0.61), URBN: 21.14 (-1.53), AGN: 296.40 (-2.31), ERIC: 9.49 (-0.05), CAT: 69.34 (-1.05), JD: 28.72 (-0.09), CSCO: 26.83 (+0.04)
Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma
Business Wire - Mon Nov 16, 3:00AM CST
--- More Than 100 Government, Non-Governmental and Private Sector Partners Driving Progress -
PFE: 33.00 (-0.16)
World Anti-Inflammatory Therapeutics Market Opportunities and Forecasts, 2020 - Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion
M2 - Mon Nov 16, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/qwnb7n/world) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth. The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period. Key Topics Covered: Chapter: 1 Introduction Chapter: 2 Executive Summary Chapter: 3 Market Overview Chapter: 4 Global Anti-Inflammatory Therapeutics Market By Indication Chapter: 5 Global Anti-Inflammatory Therapeutics Market By Drug Class Chapter: 6 Global Anti-Inflammatory Therapeutics Market By Geography Chapter: 7 Company Profiles - AbbVie Inc - Amgen Inc. - AstraZeneca PLC. - Eli Lily and Company - GlaxoSmithKline plc - Hoffmann-La Roche AG - Johnson & Johnson - Merck & Co. - Novartis AG - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/qwnb7n/world
JNJ: 101.31 (+0.09), PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), AZN: 33.33 (+0.55), AMGN: 157.88 (+3.38), ABBV: 60.22 (+0.21), GSK: 40.58 (+0.35), NVS: 87.47 (+0.42)
Better Dividend Stock: Pfizer vs. GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 6:01AM CST
Image source: GlaxoSmithKline. GlaxoSmithKline has an eye-popping dividend yield of 5.75%, but that doesn't necessarily make it the best dividend-paying option available to investors. In fact, with GlaxoSmithKline's product portfolio facing a...
PFE: 33.00 (-0.16), GSK: 40.58 (+0.35)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), AMGN: 157.88 (+3.38), LLY: 81.16 (-0.07), REGN: 568.18 (+9.80)
Big deal momentum may carry into 2016 for health care
By TOM MURPHY - AP - Fri Nov 13, 1:16PM CST
With $2 trillion in buyouts since January, 2015 has become the year of the megadeal, fueled by free money in a zero-interest rate environment.
CI: 133.79 (+0.30), ANTM: 135.70 (+0.64), PFE: 33.00 (-0.16), ANTX: 45.53 (+0.28), MYL: 50.64 (+0.64)
Allergan Is a Winner -- With or Without Pfizer Deal
at The Street - Fri Nov 13, 7:00AM CST
We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.
AGN: 296.40 (-2.31), PFE: 33.00 (-0.16), TEVA: 60.00 (+1.19)
5 Things Pfizer Inc. Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 6:39AM CST
Image source: Pfizer. Late last month, pharmaceutical juggernaut Pfizer did what it's done best over the past couple of quarters and handily surpassed Wall Street's third-quarter estimates. Pfizer's headline numbers showed that the...
PFE: 33.00 (-0.16)
3 Top Stocks for Low-Risk Investors
Timothy Green, Matthew DiLallo, and George Budwell, The Motley Fool - Motley Fool - Fri Nov 13, 6:11AM CST
Image source: GotCredit via Flickr. While the riskiest of stocks are often the ones that provide investors with amazing returns, the downside is the very real possibility of a permanent loss of capital. For every high-flying growth stock, there...
AGN: 296.40 (-2.31), PFE: 33.00 (-0.16), XOM: 79.94 (-0.96), VZ: 45.04 (unch)
Ask a Fool: What Stocks Are On Your Radar Now?
Matthew Frankel, Selena Maranjian, Jordan Wathen, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Nov 13, 6:00AM CST
Source: Flickr user Rafael Matsunaga . Here at the Fool, we have positive opinions about lots of stocks, but it wouldn't be possible or practical to buy every single stock we like. However, there are some stocks that are especially intriguing...
HAS: 74.33 (-1.44), CFR: 68.57 (-0.39), PFE: 33.00 (-0.16), CLLS: 35.27 (+0.72), ETSY: 8.79 (+0.01)
Watch for Pfizer to Potentially Rebound After Falling 1.04% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 5:01PM CST
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 33.00 (-0.16)
SmarTrend Watching for Potential Rebound in Shares of Pfizer After 1.04% Loss
Comtex SmarTrend(R) - Thu Nov 12, 5:00PM CST
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 33.00 (-0.16)
Is This The Biggest Roadblock to a Pfizer-Allergan Merger?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 7:29AM CST
Pfizer and Allergan are reportedly discussing the possibility of a friendly merger between the two pharma giants that could take place before year's end. This proposed deal has drawn broad interest in the media because of the so-called 'tax...
AGN: 296.40 (-2.31), PFE: 33.00 (-0.16)
Roche's Lung Cancer Diagnostic Test Approved in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:05PM CST
Roche announced that the FDA has approved its diagnostic test, the cobas EGFR Mutation Test v2, for companion diagnostic use.
NVO: 53.87 (+0.61), PFE: 33.00 (-0.16), AZN: 33.34 (+0.56)
The Medicines Co. Up, Angiomax Patent Ruling Overturned
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 3:40PM CST
The Medicines Company's (MDCO) request for rehearing of the appeal has been granted related to its patent infringement lawsuit for Angiomax.
MDCO: 41.16 (-0.35), PFE: 33.00 (-0.16), MYL: 50.64 (+0.64), NVS: 87.47 (+0.42)
Marriott, Not Hyatt Or Chinese Firms, To Buy Starwood
at Investor's Business Daily - Mon Nov 16, 11:18AM CST
Several companies -- including Hyatt (H) and several Chinese bidders -- had been rumored to be in talks to buy Starwood Hotels & Resorts Worldwide (HOT), but Bethesda, Md.-based Marriott International (MAR) will ultimately acquire the hotel chain in...
BUD: 124.72 (+2.33), NSC: 86.88 (-1.42), PFE: 33.00 (-0.16), IILG: 15.40 (-0.04), HAL: 38.18 (-0.31), H: 49.52 (-1.70), MAR: 72.86 (-0.86), AET: 105.34 (+0.33), HOT: 71.79 (-0.48), RAD: 7.76 (+0.02), HUM: 169.08 (+0.04), AGN: 296.40 (-2.31), CI: 133.79 (+0.30), ANTM: 135.70 (+0.64), WBA: 82.68 (+0.84), CP: 139.05 (+1.66), BHI: 49.52 (+0.13)
Next Support Level for Pfizer (PFE) is $32.82
Comtex SmarTrend(R) - Mon Nov 16, 10:18AM CST
Shares of Pfizer (NYSE
FE) opened today below their pivot of $33.36 and have already reached the first level of support at $33.05. Should the shares continue to fall, the support pivots of $32.82 and $32.28 will be of interest. PFE: 33.00 (-0.16)
3 High-Yield Dividend Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Nov 16, 8:19AM CST
Image by Markgraf-Ave via Pixabay With the S&P 500 once again in negative territory for the year, companies of all sizes have seen their share prices decline. When a stock that pays a strong dividend goes down, it has the happy effect of...
PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), ABBV: 60.22 (+0.21)
Global Anti-Inflammatory Therapeutics Market 2014-2020 by Indication, Drug Class & Geography
PR Newswire Europe - Mon Nov 16, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/8rkdpz/world [http://www.researchandmarkets.com/research/8rkdpz/world]) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" [http://www.researchandmarkets.com/research/8rkdpz/world] report to their offering.
JNJ: 101.31 (+0.09), PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), AZN: 33.33 (+0.55), AMGN: 157.88 (+3.38), ABBV: 60.22 (+0.21), GSK: 40.58 (+0.35), NVS: 87.47 (+0.42)
Nov. 16 Premarket Briefing: Marriott to Buy Starwood
at The Street - Mon Nov 16, 6:00AM CST
U.S. stock futures rise Monday, while European stocks are mixed in choppy trading following the terrorist attacks in Paris on Friday that left at least 129 people dead.
GE: 30.01 (-0.35), CCL: 50.19 (-0.58), A: 38.23 (+0.90), PFE: 33.00 (-0.16), MAR: 72.86 (-0.86), HOT: 71.79 (-0.48), DDS: 73.13 (+0.61), URBN: 21.14 (-1.53), AGN: 296.40 (-2.31), ERIC: 9.49 (-0.05), CAT: 69.34 (-1.05), JD: 28.72 (-0.09), CSCO: 26.83 (+0.04)
Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma
Business Wire - Mon Nov 16, 3:00AM CST
--- More Than 100 Government, Non-Governmental and Private Sector Partners Driving Progress -
PFE: 33.00 (-0.16)
World Anti-Inflammatory Therapeutics Market Opportunities and Forecasts, 2020 - Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion
M2 - Mon Nov 16, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/qwnb7n/world) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth. The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period. Key Topics Covered: Chapter: 1 Introduction Chapter: 2 Executive Summary Chapter: 3 Market Overview Chapter: 4 Global Anti-Inflammatory Therapeutics Market By Indication Chapter: 5 Global Anti-Inflammatory Therapeutics Market By Drug Class Chapter: 6 Global Anti-Inflammatory Therapeutics Market By Geography Chapter: 7 Company Profiles - AbbVie Inc - Amgen Inc. - AstraZeneca PLC. - Eli Lily and Company - GlaxoSmithKline plc - Hoffmann-La Roche AG - Johnson & Johnson - Merck & Co. - Novartis AG - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/qwnb7n/world
JNJ: 101.31 (+0.09), PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), AZN: 33.33 (+0.55), AMGN: 157.88 (+3.38), ABBV: 60.22 (+0.21), GSK: 40.58 (+0.35), NVS: 87.47 (+0.42)
Better Dividend Stock: Pfizer vs. GlaxoSmithKline
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 6:01AM CST
Image source: GlaxoSmithKline. GlaxoSmithKline has an eye-popping dividend yield of 5.75%, but that doesn't necessarily make it the best dividend-paying option available to investors. In fact, with GlaxoSmithKline's product portfolio facing a...
PFE: 33.00 (-0.16), GSK: 40.58 (+0.35)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.00 (-0.16), MRK: 53.71 (+0.01), AMGN: 157.88 (+3.38), LLY: 81.16 (-0.07), REGN: 568.18 (+9.80)
Big deal momentum may carry into 2016 for health care
By TOM MURPHY - AP - Fri Nov 13, 1:16PM CST
With $2 trillion in buyouts since January, 2015 has become the year of the megadeal, fueled by free money in a zero-interest rate environment.
CI: 133.79 (+0.30), ANTM: 135.70 (+0.64), PFE: 33.00 (-0.16), ANTX: 45.53 (+0.28), MYL: 50.64 (+0.64)
Allergan Is a Winner -- With or Without Pfizer Deal
at The Street - Fri Nov 13, 7:00AM CST
We'd love to see Pfizer acquire Allergan, but it isn't the only reason we're in the name.
AGN: 296.40 (-2.31), PFE: 33.00 (-0.16), TEVA: 60.00 (+1.19)
5 Things Pfizer Inc. Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 6:39AM CST
Image source: Pfizer. Late last month, pharmaceutical juggernaut Pfizer did what it's done best over the past couple of quarters and handily surpassed Wall Street's third-quarter estimates. Pfizer's headline numbers showed that the...
PFE: 33.00 (-0.16)
3 Top Stocks for Low-Risk Investors
Timothy Green, Matthew DiLallo, and George Budwell, The Motley Fool - Motley Fool - Fri Nov 13, 6:11AM CST
Image source: GotCredit via Flickr. While the riskiest of stocks are often the ones that provide investors with amazing returns, the downside is the very real possibility of a permanent loss of capital. For every high-flying growth stock, there...
AGN: 296.40 (-2.31), PFE: 33.00 (-0.16), XOM: 79.94 (-0.96), VZ: 45.04 (unch)
Ask a Fool: What Stocks Are On Your Radar Now?
Matthew Frankel, Selena Maranjian, Jordan Wathen, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Nov 13, 6:00AM CST
Source: Flickr user Rafael Matsunaga . Here at the Fool, we have positive opinions about lots of stocks, but it wouldn't be possible or practical to buy every single stock we like. However, there are some stocks that are especially intriguing...
HAS: 74.33 (-1.44), CFR: 68.57 (-0.39), PFE: 33.00 (-0.16), CLLS: 35.27 (+0.72), ETSY: 8.79 (+0.01)
Watch for Pfizer to Potentially Rebound After Falling 1.04% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 5:01PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 33.00 (-0.16)
SmarTrend Watching for Potential Rebound in Shares of Pfizer After 1.04% Loss
Comtex SmarTrend(R) - Thu Nov 12, 5:00PM CST
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $33.35 to a high of $33.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $33.39 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 33.00 (-0.16)
